Reference health
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
44/44 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 44 checked references that resolve
resolves10.1007/s10654-021-00808-7
Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States
resolves10.15585/mmwr.mm7031e2
Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021
resolves10.15585/mmwr.mm7028e2
SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility — Oklahoma, April–May 2021
resolves10.2807/1560-7917.ES.2021.26.39.2100822
Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021
resolves10.1016/j.eclinm.2021.101143
An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
resolves10.1016/j.clim.2021.108860
Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey
resolves10.1038/s41591-021-01469-5
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
resolves10.1136/annrheumdis-2020-218296
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
resolves10.1002/acr2.11329
Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
resolves10.1016/S2665-9913(21)00327-1
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
resolves10.1016/S2666-5247(21)00025-2
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study
resolves10.1080/22221751.2021.1996210
Antibody response elicited by a third boost dose of inactivated SARS-CoV-2 vaccine can neutralize SARS-CoV-2 variants of concern
resolves10.1016/S2665-9913(21)00328-3
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
resolves10.1016/S0140-6736(21)02249-2
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
resolves10.1016/S0140-6736(21)01699-8
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
resolves10.1053/j.ajkd.2021.08.005
SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
resolves10.1001/jama.2021.12339
Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses
resolves10.1016/j.kint.2021.09.014
Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients
resolves10.1111/bjh.17911
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
resolves10.1101/2021.07.02.21259913
Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study
resolves10.1056/NEJMc2111462
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
resolves10.1056/NEJMc2108861
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
resolves10.3390/vaccines9101055
Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia
resolves10.1002/art.27584
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
resolves10.1002/art.34473
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
resolves10.1136/ard.2009.108233
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
resolves10.3899/jrheum.110845
The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study: Table 1.
resolves10.1002/art.1780330811
The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis
resolves10.1002/art.1780330807
The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis
resolves10.1136/ard.61.6.554
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
resolves10.1136/annrheumdis-2013-204424
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
resolves10.1136/annrheumdis-2017-211468
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
resolves10.1111/j.1538-7836.2006.01753.x
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
resolves10.1128/JCM.02438-20
A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection
resolves10.1056/NEJMoa2114583
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
resolves10.1016/j.healun.2021.08.010
Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience
resolves10.1136/annrheumdis-2021-221916
Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
resolves10.7326/L21-0282
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
resolves10.15585/mmwr.mm7044e3
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021
resolves10.1093/ndt/gfab299
Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders
resolves10.1038/s41591-021-01542-z
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
resolves10.1038/s41591-021-01377-8
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
The 6 references without a DOI — listed, not checked
no DOI — not checkedNew COVID-19 cases and hospitalizations among adults, by vaccination status — New York, may 3–July 25, 2021
no DOI — not checked10.1136/annrheumdis-2021-222096_bib8
no DOI — not checkedSilva CA, Medeiros-Ribeiro AC, Kupa LVK,. Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic disease patients: phase 4 prospective trial, 23 November 2021, PREPRINT (version 1) available at research square.
no DOI — not checkedA third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients
no DOI — not checkedImmunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
no DOI — not checkedAmerican College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases – version 3
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1136/annrheumdis-2021-222096"><img src="https://citestamp.com/citestamped/10.1136/annrheumdis-2021-222096/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1136/annrheumdis-2021-222096)